Mouse models of thyroid cancer: Bridging pathogenesis and novel therapeutics

This publication has 241 references indexed in Scilit:

• RETRACTED ARTICLE: Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancer
  Journal of Cancer Research and Clinical Oncology, 2013
• Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial
  The Lancet Oncology, 2012
• STAT3 negatively regulates thyroid tumorigenesis
  Proceedings of the National Academy of Sciences, 2012
• Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer
  Investigational New Drugs, 2012
• Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
  Journal of Clinical Oncology, 2012
• A novel RET inhibitor with potent efficacy against medullary thyroid cancer in vivo
  Surgery, 2010
• Thyroidectomy with neoadjuvant PLX4720 extends survival and decreases tumor burden in an orthotopic mouse model of anaplastic thyroid cancer
  Surgery, 2010
• Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
  The Lancet Oncology, 2010
• B-Raf^V600Eand thrombospondin-1 promote thyroid cancer progression
  Proceedings of the National Academy of Sciences, 2010
• Canonical and non-canonical JAK–STAT signaling
  Trends in Cell Biology, 2008